GlassScriptPhysician profile
Nathan J Kroegel
NPI 1811237514
$2,624.59
in general payments reported to CMS, 2019-2025
19 companies · $839 in 2025
The $839 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $207 · 2022: $398 · 2023: $285 · 2024: $895 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $827.47 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $299.34 | 2024-2025 | Caplyta |
| Tris Pharma INC | $233.30 | 2022-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $170.40 | 2023-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $131.04 | 2021-2024 | Spravato |
| Lundbeck LLC | $119.94 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $119.82 | 2023-2025 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $115.72 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $110.28 | 2023-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $87.76 | 2024-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $77.73 | 2023-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $71.32 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $62.58 | 2024-2025 | Fanapt |
| Alkermes, INC. | $61.83 | 2022-2025 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $39.51 | 2024 | Rexulti, Abilify Asimtufii |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $37.10 | 2024-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $29.99 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $16.00 | 2024 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $13.46 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Kroegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.